SMC2 and cancer: Of note, the combination of a classical chemotherapeutic agent with Ab-SMC2 was non-deleterious for both encapsulated 5-FU and PTX formulations offering the possibility of eliminating both subpopulations simultaneously, CSC and “bulk” or differentiated cancer cells.